The invention describes an efficient platform for antibody manufacturing and formulation that provides i) cell culture process with improved feeding strategy resulting in high antibody titer between 2 gm/L to 5 gm/L； ii) improved purification process showing optimal percentage recovery, high purity monomer content, minimum aggregation/particulate formation, minimum impurity levels； and iii) high concentration stable liquid formulation with optimal osmolality and low viscosity across different temperature excursions and devoid of aggregation. The preferred antibodies include IgG1 monoclonal antibody specific to the Dengue virus epitope in domain III of the E protein and IgG1 monoclonal antibody specific to the rabies virus surface G glycoprotein.本發明描述用於抗體製造及配製之有效平臺，其提供i)利用改進的進料策略之細胞培養製程，其產生在2 gm/L至5 gm/L之間的高抗體效價；ii)改進的純化製程，其展示最佳回收百分比、高純度單體含量、最小聚集/微粒形成、最小雜質水平；及iii)高濃度穩定的液體配方，其具有跨於不同溫度偏離額定值之最佳滲透壓度及低黏度且缺少聚集。較佳抗體包括對E蛋白質之結構域III中的登革熱病毒抗原決定基特異的IgG1單株抗體及對狂犬病病毒表面G糖蛋白特異的IgG1單株抗體。
